Press Release

INDGN/SE/2026-27/57 06 October 2026 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN Dear Sir / Madam, Subject: Press Release Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the copy of Press Release titled “Indegene Digital Summit 2026 - National Constitution Center, Philadelphia” being submitted in addition to the Press Release titled “From Promise to Performance: Life Sciences Leaders Focus on Operationalizing AI to Deliver Enterprise Outcomes at Indegene Digital Summit 2026” filed with the Stock Exchanges on 23 September, 2026. This will also be posted on the company’s website at: https://www.indegene.com/ We request you to kindly take the same on record. Thanking You Yours Sincerely, For Indegene Limited Srishti Ramesh Kaushik Company Secretary and Compliance Officer Encl: A/a Indegene Limited Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru- 560 045, Karnataka, India Phone: +91 80 4674 4567, +91 80 4644 7777 compliance.officer@indegene.com www.indegene.com CIN: L73100KA1998PLC102040 Indegene Digital Summit 2026 National Constitution Center, Philadelphia www.indegene.com IDS 2026: Our Most Influential Summit Yet Keynotes Panels and presentations Keynote Speakers 120+ (50%+ decision makers & sponsors) Pharma attendees (40% more Pharma participation than David Shulkin Amol Punjabi Agam Upadhyay Corinne Le Goff 2025) Ninth Secretary Chief Product Officer Chief Digital & Chief Commercial Speakers U.S. Department of OpenEvidence Information Officer Officer Veterans Affairs Vertex Viatris © 2026 Indegene. All rights reserved. 2 Beyond Pharma: Expanding the Conversation IDS is increasingly attracting voices influencing healthcare policy, AI adoption, and enterprise transformation. • Industry Leaders: Commercial, medical, digital, data and technology executives. • External Catalysts: AI innovators, policymakers and thought leaders. • Strategic Topics: AI operating models, customer engagement, enterprise transformation and future of work From Industry Participant to Industry Convenor Pharma CEOs and Digital & Commercial Technology AI Innovators • 120+ senior pharma leaders attended (50% decision Leaders Leaders makers, 70% Director+) • Representation from commercial, medical, digital, technology, and enterprise leadership functions Policymakers & • Strong participation from both large pharma and Industry Analysts & Government emerging biopharma companies Researchers Leaders (Former) • Expanded speaker roster and greater executive representation than previous editions © 2026 Indegene. All rights reserved. 3 Establishing Leadership in AI-Native Pharma Enablement 410+ Minutes of Sessions Shifting the industry conversation from 'How can AI work in Pharma?’ to 'How do we operationalize AI at scale?' The Moment That Surprised the Industry Indegene's AI and platform capabilities emerged as one of the strongest themes of the summit. 8 sessions exploring the impact and performance of AI from industry, leader and capability POVs, offering a direct view into the depth of Indegene's capabilities. Bringing the Indegene Story to Life Indegene AI Experience Zone From isolated capability kiosks in previous years to an integrated end-to-end experience, one connected client journey across strategy, content and engagement IDS has evolved into a trusted forum for the life sciences ecosystem Emerging as an Industry Institution • IDS is becoming a flagship platform for Future Ready Healthcare. • IDS has established differentiation in its role as a platform for peer-to-peer exchange. • Celebrating Industry Leadership Through the Vital Awards, recognizing leaders driving measurable impact across healthcare. A Venue Symbolizing Leadership and Enduring Ideas Experiences Philadelphia: Reinforcing Our Strength in the U.S. Market • National Constitution Center, Philadelphia - The venue reinforced the Freedom Rising Show summit's focus on leadership, transformation, and the future of life sciences. • IDS strengthened executive engagement across the U.S. life sciences ecosystem. • Delivered a premium executive experience with the 'Freedom Rising Show' and other experience zones, enabling deeper engagement with existing and prospective clients. Museum and Exhibits Connected Experience zone IDS 2026: What it signals 1. For the Industry: A shift from AI experimentation to enterprise transformation. 2. For Clients: A trusted platform to exchange ideas and accelerate change. 3. For Indegene: Growing influence as a strategic partner, AI innovator, and industry convenor. 4. For Investors: Evidence that Indegene's investments in AI, platforms, domain expertise, and ecosystem leadership are strengthening its strategic position within life sciences. Key Takeaways: Executive Summary FROM PROMISE TO PERFORMANCE: What IDS 2026 Revealed 1. AI success depends on reimagined operating models, not technology alone. 2. Customer attention is shifting toward AI-mediated discovery and evidence-led engagement. 3. Governance, workflow redesign, and business ownership are becoming critical for enterprise scale. 4. Agile organizations will outperform by combining human expertise, AI intelligence, and continuous learning. 5. The next competitive advantage in life sciences will come from turning AI capability into measurable business performance Thank You! www.indegene.com Sessions Keynote Fireside Chat From Push to Intent: Navigating Point-of-Care AI with OpenEvidence Speakers Key Takeaways AI is reshaping physician decision-making, making evidence quality the new driver of influence. • Trusted evidence increases visibility in AI-assisted care. • HCP engagement is shifting from education to partnership. • Real-world insights should inform development earlier. Panel Discussion The Attention Crisis: Why Healthcare Engagement Needs a New Model Speakers Key Takeaways Customer influence now happens before traditional pharma engagement begins. • Relevance matters more than operational efficiency. • Authority and trust outperform content volume. • Operating models must evolve faster than ever. Panel Discussion Customer Engagement in 2028: What will it take to earn your customer's attention? Speakers Key Takeaways Future engagement will be defined by customer intelligence, not channel reach. • Engagement is moving from persuasion to co-creation. • Unified customer profiles enable seamless experiences. • Enterprise AI governance must span the value chain. Panel Discussion The Future of Work: Rethinking Talent, Partners & Investments Speakers Key Takeaways AI transformation succeeds when organizations redesign work, not simply automate it. • Break traditional brand and channel silos. • Redesign workflows before deploying AI. • Adoption depends on employee value and engagement. Keynote Address from our CTO Speaker Key Takeaways Domain expertise remains the differentiator in an AI-native world. • Expert knowledge dramatically improves agent performance. • Continuous feedback creates ongoing optimization. • AI shifts experts from creators to reviewers Keynote Fireside Chat The Role of the CDIO as the Architect of Pharma's AI agenda Speakers Key Takeaways Enterprise AI impact comes from prioritization, governance, and process reinvention. • Focus on a few high-value problems. • Reimagine processes before automating them. • Governance enables innovation at scale. Keynote Address Elevating CX through Digital Capabilities, Global Operating Model & Change management Speakers Key Takeaways Transformation accelerates when business strategy, operations, and technology move together. • Executive sponsorship drives adoption. • Integrated operating models outperform fragmented structures. [Showing first 8,000 characters — download PDF for full document]